BioCentury
ARTICLE | Company News

Dyax, Shire deal

February 1, 2016 8:00 AM UTC

Shire completed its acquisition of Dyax for $37.50 per share, or $5.9 billion in cash. Dyax shareholders also are eligible for a contingent value right (CVR) worth $4 per share, or $646 million, if FD...